Project Grant R01HL183959
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $671K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $701,116 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to investigate transcriptional mutagenesis as a novel mechanism driving heart failure. The research examines how oxidative stress promotes formation of 8-oxo-deoxyguanosine lesions in DNA, which disrupts transcriptional fidelity in cardiomyocytes. Aim 1 integrates long-read single-nucleus RNA sequencing from human heart...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $625,035 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research into the molecular mechanisms of mitochondrial calcium exchange in the heart. The research addresses mitochondrial calcium overload, which triggers cell death and tissue damage during ischemia-reperfusion injury—a secondary phase of cardiac damage that can account for up to 50 percent of final infarct...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $765,811 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate fatty acid oxidation and myosteatosis in peripheral artery disease. The research project examines the role of fatty acid oxidation in limb tissue mitochondria as a cause of myosteatosis and chronic limb-threatening ischemia presentations, and explores it as a site for interventional therapies. The...
- Federal Grant Award Summary Baylor College of Medicine received a $673,598 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with a completion date of June 30, 2029. The project, "Cardiomyocyte-Fibroblast Signaling in Atrial Fibrillation," delivers basic and translational research services investigating molecular mechanisms underlying atrial fibrillation (AF), a...
- The National Heart Lung and Blood Institute awarded Northwestern University $2,139,171 under Project Grant R01HL184083 on September 1, 2026, to conduct epidemiological and mechanistic research linking ectopic fat with inflammation and atherosclerosis. The research addresses gaps in understanding how distinct fat depots—hepatic, visceral, epicardial, and pericoronary—drive local vascular inflammation and coronary plaque formation across populations. Northwestern will leverage two...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $799,920 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to establish mechanistic connections between chronic liver dysfunction and atrial arrhythmogenesis and to develop targeted therapeutic interventions. The project investigates the relationship between metabolic dysfunction-associated steatohepatitis (MASH) and atrial fibrillation (AF) risk. Research activities include...
- The National Heart, Lung, and Blood Institute awarded Baylor University $562,494 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026 for a Project Grant (R15HL179650) to identify metabolic drivers of cancer cachexia-associated cardiomyopathy. The research will use pre-clinical cancer cachexia mouse models to identify the role of mitochondrial dysfunction on metabolism and mechanical function in hearts and cardiac muscle cells from mice with cancer cachexia. Mice...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Brigham & Women's Hospital Inc. $1.789 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds integrative computational-experimental approaches to identify rare coding variants that influence lipid metabolism and cardiovascular disease risk. The research combines large-scale population cohort data with high-throughput functional screening using base and prime...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $132,452 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate genetic, metabolic, and sociodemographic factors underpinning pediatric out-of-hospital cardiac arrest. The research expands on prior population-based work evaluating more than 900 children with cardiac arrest. Baylor will evaluate oligogenic patterns in a large cohort of children with cardiac arrest,...